A bispecific monoclonal antibody T‑cell engager (REGN5458) that binds BCMA on myeloma cells and CD3 on T cells to redirect CD3+ T cells to kill BCMA+ malignant plasma cells.
Linvoseltamab (REGN5458) is a bispecific antibody that binds BCMA on multiple myeloma cells and CD3 on T cells, redirecting and activating CD3+ T cells to form cytolytic synapses and kill BCMA-expressing malignant plasma cells.
NO
INDIRECT
The drug binds CD3 epsilon on T cells to activate and redirect them; these T cells then kill BCMA-expressing myeloma cells via cytolytic synapses (perforin/granzyme). CD3+ T cells are not the targets killed.
Ac-225–labeled GPC3-binding radioligand therapy that delivers short-range, high-LET alpha particles to GPC3-positive cells, inducing DNA double-strand breaks and cell death.
RYZ801 is an Ac-225–labeled GPC3-targeted radioligand that binds GPC3 on tumor cells and delivers short-range, high–linear energy transfer alpha particles. The emitted alpha radiation causes clustered DNA double-strand breaks in GPC3-positive cells, leading to irreparable damage and cell death while limiting off-target exposure due to the short path length.
YES
DIRECT
The Ac-225–labeled GPC3-targeted radioligand binds GPC3 and emits short-range alpha particles that induce clustered DNA double-strand breaks in GPC3-positive cells, causing irreversible damage and cell death.
An intravenously administered tetra-specific antibody (biologic immunotherapy) engineered to engage CD3 on T cells and recognize multiple B-cell-associated antigens to redirect and activate T cells against B-cell lymphoma, aiming to enhance cytotoxicity, provide costimulation/checkpoint modulation, and reduce antigen escape.
Tetra-specific T-cell–redirecting antibody that binds CD3 on T cells, CD19 on B-cell lymphomas, PD-L1 to block PD-1–mediated inhibition, and 4-1BB to provide costimulation. By crosslinking T cells to CD19+ tumor cells, it induces CTL-mediated killing while concurrently enhancing activation and persistence and reducing antigen escape.
YES
DIRECT
By binding CD3 on T cells and CD19 on target cells, it crosslinks and activates T cells (augmented by 4-1BB costimulation and PD-L1 blockade) to kill CD19+ cells via perforin/granzyme-mediated cytotoxicity.
An intravenously administered tetra-specific antibody (biologic immunotherapy) engineered to engage CD3 on T cells and recognize multiple B-cell-associated antigens to redirect and activate T cells against B-cell lymphoma, aiming to enhance cytotoxicity, provide costimulation/checkpoint modulation, and reduce antigen escape.
Tetra-specific T-cell–redirecting antibody that binds CD3 on T cells, CD19 on B-cell lymphomas, PD-L1 to block PD-1–mediated inhibition, and 4-1BB to provide costimulation. By crosslinking T cells to CD19+ tumor cells, it induces CTL-mediated killing while concurrently enhancing activation and persistence and reducing antigen escape.
NO
INDIRECT
CD3 is an engager on T cells. GNC-038 binds CD3 to recruit and activate T cells, which then kill CD19+ tumor cells (with 4-1BB costimulation and PD-L1 blockade). CD3+ T cells are not targeted for killing.
An intravenously administered tetra-specific antibody (biologic immunotherapy) engineered to engage CD3 on T cells and recognize multiple B-cell-associated antigens to redirect and activate T cells against B-cell lymphoma, aiming to enhance cytotoxicity, provide costimulation/checkpoint modulation, and reduce antigen escape.
Tetra-specific T-cell–redirecting antibody that binds CD3 on T cells, CD19 on B-cell lymphomas, PD-L1 to block PD-1–mediated inhibition, and 4-1BB to provide costimulation. By crosslinking T cells to CD19+ tumor cells, it induces CTL-mediated killing while concurrently enhancing activation and persistence and reducing antigen escape.
NO
INDIRECT
PD-L1 binding serves checkpoint blockade and costimulation; T cells are redirected via CD3×CD19 engagement to kill CD19+ cells, not PD-L1+ cells specifically.